FDA 483 OBSERVATION · #107 OF 1,923 MOST-CITED
Establish, maintain and follow manufacturing SOPs
FDA cited this observation 279 times across 236 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A dietary-supplement manufacturer did not establish, maintain, and follow the written procedures required for its manufacturing operations, so the production and process controls were not defined and consistently applied.
Why FDA writes it — Written procedures are the backbone of dietary-supplement CGMP — the rule explicitly requires them for the manufacturing operations. Without established and followed SOPs, production is uncontrolled and cannot be shown to be consistent.
- Establish and follow written procedures for the manufacturing operations required by 21 CFR 111 subpart E.
- Cover the batch production record, in-process controls, and the steps needed to ensure specifications are met.
- Train personnel to the procedures and document the training.
- Keep procedures current through change control and follow them in practice.
- Required manufacturing SOPs never established, so operations run on undocumented practice.
- SOPs exist but are not followed, so practice and procedure diverge.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.1× the rate of the average FDA-cited firm (0.4% vs 7.8%), across 236 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Written standard operating procedures including all steps to be followed in the collection of blood and blood components for allogeneic transfusion were not always followed.
Written standard operating procedures including all steps to be followed in the collection, processing, compatibility testing, storage and distribution of blood and blood components for further manufacturing purposes were not always maintained.
Written standard operating procedures including all steps to be followed in the distribution of blood and blood components for further manufacturing purposes were not always followed.
Written standard operating procedures including all steps to be followed in the collection of blood and blood components for allogeneic transfusion and autologous transfusion were not always established, maintained and followed.
Written standard operating procedures including all steps to be followed in the storage of blood and blood components for allogeneic transfusion were not always followed.
Written standard operating procedures including all steps to be followed in the storage and distribution of blood and blood components for allogeneic transfusion, autologous transfusion and further manufacturing purposes were not always established, maintained and followed.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →